Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21123543 | 1.00 | CRBN (0.41) | CRBNALDH1A1LMNADDB1CALCRL | |
| SCHEMBL21084102 | 1.00 | CRBN (0.41) | CRBNALDH1A1LMNADDB1CALCRL | |
| SCHEMBL21123556 | 0.92 | CALCRL (0.42) | CRBNALDH1A1LMNADDB1CALCRL | |
| SCHEMBL19718133 | 0.92 | CALCRL (0.42) | CRBNALDH1A1LMNADDB1CALCRL | |
| SCHEMBL21123789 | 0.92 | CALCRL (0.42) | CRBNALDH1A1LMNADDB1CALCRL | |
| SCHEMBL18159342 | 0.91 | CRBN (0.41) | CRBNALDH1A1LMNADDB1CA12 | |
| SCHEMBL18148486 | 0.91 | CRBN (0.41) | CRBNALDH1A1LMNADDB1CA12 | |
| SCHEMBL18148370 | 0.91 | CRBN (0.41) | CRBNALDH1A1LMNADDB1CA12 | |
| SCHEMBL18145089 | 0.91 | CRBN (0.41) | CRBNALDH1A1LMNADDB1CA12 | |
| SCHEMBL18144771 | 0.91 | CRBN (0.41) | CRBNALDH1A1LMNADDB1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12213969-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO HEALTH, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20230414585-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | VALO EARLY DISCOVERY, INC. | 2023-12-28 | — | — | US | disclosed |
| US-11730721-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO HEALTH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730721-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO HEALTH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730721-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO HEALTH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210186940-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2021-06-24 | — | — | US | disclosed |
| US-10874649-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200121655-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | Valo Health, LLC | 2020-04-23 | — | — | US | disclosed |
| US-10555935-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190201384-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | Valo Health, LLC | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414585-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | HDAC5, HDAC2, HDAC1 | CRBN 1220/4885ALDH1A1 153/4885LMNA 4210/4885 |
| US-20210186940-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | HDAC5, HDAC2, HDAC1 | CRBN 1220/4885ALDH1A1 153/4885LMNA 4210/4885 |
| US-10874649-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | HDAC5, HDAC2, HDAC1 | CRBN 1220/4885ALDH1A1 153/4885LMNA 4210/4885 |
| US-10555935-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | HDAC5, HDAC2, HDAC1 | CRBN 1220/4885ALDH1A1 153/4885LMNA 4210/4885 |
| US-20190201384-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | HDAC5, HDAC2, HDAC1 | CRBN 1220/4885ALDH1A1 153/4885LMNA 4210/4885 |
| US-12213969-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | HDAC5, HDAC2, HDAC1 | CRBN 1220/4885ALDH1A1 153/4885LMNA 4210/4885 |
| US-20200121655-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | HDAC5, HDAC2, HDAC1 | CRBN 1220/4885ALDH1A1 153/4885LMNA 4210/4885 |
| US-11730721-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | HDAC5, HDAC2, HDAC1 | CRBN 1220/4885ALDH1A1 153/4885LMNA 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.